5 FDA COVID-19 Decisions in July Could Make or Break Stocks
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Insurance company Lemonade entered the market with a bang on Thursday.
Francesca’s shares more than doubled on Thursday after the company announced the development of its first mobile e-commerce application.
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
A lot of Apple stock’s recent momentum has been due to the excitement around the upcoming iPhone 12 and 5G. Is there a wave of new purchases of smartphones, personal computers and tablets coming…
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
FedEx reported fiscal fourth-quarter financial results after markets closed Tuesday. The firm reported $2.53 in earnings per share (EPS) and $17.4 billion in revenue, compared with consensus estimates that called for $1.52 in EPS…
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.
9 Meters Biopharma may not be a household name right now, but one brokerage firm sees huge potential upside.
Investors appear to be happy with the Micron Technology quarterly report, and analysts agreed, hiking their price targets in response.
Conagra Brands reported better than expected fiscal fourth-quarter financial results before the markets opened on Tuesday.
DRAM maker Micron reported fiscal third-quarter earnings per share of $0.82and $5.44 billion in revenue. The consensus estimates called for $0.77 in per-share profit and $5.31 billion in revenue.
Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
News that Landcadia Holdings II aims to acquire Golden Nugget Online Gaming had its shares jumping to start out the week.
More investors now consider waste removal and cleaning company BioHiTech Global to be among those on the growing list of COVID-19 stocks. Thus, its shares more than doubled to start out the week.
Gilead has priced its COVID-19 drug candidate at $2,340 for a five-day treatment in the United States and some other developed countries. The company set the price for a single vial of remdesivir at…
Intercept Pharmaceuticals stock was crushed early on Monday after the firm received an update from the FDA in regards to its treatment of fibrosis due to nonalcoholoic steatohepatitis.